Bevacizumab In Hereditary Hemorrhagic Telangiectasia
Bevacizumab In Hereditary Hemorrhagic Telangiectasia
Active, not recruiting · NCT04404881 · Registry updated 2026-05-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Bevacizumab In Hereditary Hemorrhagic Telangiectasia | Cardiovascular Abnormalities, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, cardiovascular disorder, hematologic disorder, hemorrhagic disease, hereditary hemorrhagic telangiectasia, telangiectasis, vascular disorder, vascular hemostatic disease, vascular malformation | Active, not recruiting | Phase 2 | 2026-05-05 | NCT04404881 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Hanny Al-Samkari, MD | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Massachusetts General Hospital | Boston | United States | 39 |